21:57 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

RBX2660: Ph IIb data

Data from the blinded portion of the North American Phase IIb PUNCH CD2 trial in 127 patients with recurrent CDI showed that 1 or 2 enema administrations of RBX2660 led to treatment success in 63.9%...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Integrin avβ3 (CD51/CD61)

Cancer INDICATION: Cancer In vitro and mouse studies identified a protein inhibitor of the integrin CD51/CD61 that could help treat cancer. In silico analysis of the binding interaction of CD2 analogs with CD51/CD61 and in...
08:00 , Feb 17, 2011 |  BC Innovations  |  Tools & Techniques

Engineering protein stability

Two American teams have proposed distinct strategies to improve the stability of recombinant proteins. The techniques could be used to increase the manufacturing yield, shelf life and potentially the duration of efficacy of biologics, including...
08:00 , Feb 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) CD58 Genetic association studies identified a variant at the CD58 locus that could protect against...
07:00 , Jun 23, 2008 |  BioCentury  |  Regulation

Ustekinumab vs. other biologics

Ustekinumab vs. other biologics Compound [target] Safety issues (A) Study [pts] Dosing PASI 75 (B) In registration Ustekinumab [IL-12, IL-23] Notable safety issues discussed at last week’s FDA panel meeting included risks of infections and...
07:00 , Jun 23, 2008 |  BioCentury  |  Regulation

The Pastiche of risk

The discussion at last week’s Dermatologic and Ophthalmic Drugs Advisory Committee review of Johnson & Johnson’s ustekinumab to treat moderate-to-severe plaque psoriasis illustrates the tension in today’s regulatory environment for a compound that is clearly...
07:00 , Oct 8, 2007 |  BioCentury  |  Product Development

PASI 75 comparisons

PASI 75 comparisons PASI 75 comparisons Based on Phase III data announced last week for plaque psoriasis, Johnson & Johnson's ustekinumab (CNTO 1275) looks to be as good as the two best biologics - Humira...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Clinical News

Amevive alefacept: Phase II start

Astellas plans to begin an international Phase II trial of ASP045. The company acquired worldwide rights to the product, which it markets as Amevive alefacept to treat psoriasis, from Biogen Idec Inc. (BIIB, Cambridge, Mass.)...
08:00 , Nov 21, 2005 |  BC Week In Review  |  Clinical News

Amevive alefacept: Additional Phase II data

Additional data from an international Phase II trial in 185 patients showed that Amevive plus methotrexate (MTX) led to significant improvement in disease and lowered disease progression vs. placebo plus MTX after 24 weeks. The...
07:00 , Oct 24, 2005 |  BioCentury  |  Product Development

Remicade's psoriasis advantage

Remicade infliximab looks to be more than twice as effective as other biologics marketed to treat moderate to severe plaque psoriasis, based on data published inthe Lancet earlier this month. The only drug for which...